Logo

Antengene Receives IND Approval for P-III SIENDO Trial of XPOVIO (Selinexor) to Treat Advanced or Recurrent Endometrial Cancer in China

Share this

Antengene Receives IND Approval for P-III SIENDO Trial of XPOVIO (Selinexor) to Treat Advanced or Recurrent Endometrial Cancer in China

Shots:

  • The NMPA has approved the IND application for the P- III SIENDO trial to evaluate the safety and efficacy of selinexor for advanced or recurrent endometrial cancer. The trial is being conducted over 80 centers across North America- Europe- and Asia and the results are expected in H2’2021
  • Antengene holds the exclusive development and commercial rights for the therapy in Asia-Pacific markets and is currently conducting 5 clinical trials of selinexor for the treatment of MM- DLBCL- NSCLC and peripheral T & NK/T-cell lymphoma
  • Selinexor is first in class oral selective inhibitor and 1st FDA-approved drug for use in both MM and DLBCL. The company has submitted NDAs for therapy in Asia Pacific markets

  Ref: PRNewswire | Image: PRNewswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions